# Urinary Tract Infections: Beyond Empiric Cipro ## Overview Urinary tract infections are the most common bacterial infections encountered in clinical practice. One of the most critical stewardship challenges is distinguishing true UTI from asymptomatic bacteriuria, a distinction that directly impacts antibiotic appropriateness. Fluoroquinolone overuse has driven resistance and Clostridioides difficile infection, making narrow-spectrum agents the preferred choice for uncomplicated UTI. UTIs are classified as uncomplicated cystitis, complicated UTI, pyelonephritis, or catheter-associated UTI (CAUTI), and each category carries different diagnostic and therapeutic implications. ## Distinguishing UTI from Asymptomatic Bacteriuria ### Asymptomatic Bacteriuria (ASB) Asymptomatic bacteriuria is defined as significant bacterial growth in urine culture (at or above 10^5 CFU/mL) without urinary symptoms. In most populations, ASB should not be treated because treatment does not reduce morbidity and promotes resistance. Only two populations require treatment of ASB: pregnant women, due to the risk of pyelonephritis and preterm labor, and patients undergoing urologic procedures with mucosal disruption. Common situations where ASB is overtreated include elderly patients in nursing homes, foul-smelling urine, chronic catheterization, altered mental status without other signs of infection, and pyuria alone. ### Key Principle Pyuria does not equal UTI. Pyuria is present in many non-infectious conditions and in asymptomatic bacteriuria. Bacteriuria plus pyuria without symptoms equals ASB, not UTI. Clinicians should not culture urine in patients without urinary symptoms, as doing so initiates a cascade of unnecessary treatment. Decision algorithm distinguishing asymptomatic bacteriuria from true urinary tract infection based on presence of urinary symptoms, with populations where ASB treatment is indicated ## Uncomplicated Cystitis ### Definition Uncomplicated cystitis is a UTI occurring in a non-pregnant, premenopausal woman with normal urinary tract anatomy. Symptoms include dysuria, frequency, urgency, and suprapubic pain. The absence of fever, flank pain, and systemic symptoms distinguishes cystitis from upper tract infection. ### Diagnosis Clinical diagnosis is often sufficient, and empiric treatment without urinalysis or culture is acceptable in a classic presentation. On urinalysis, positive leukocyte esterase and/or nitrites supports the diagnosis. Urine culture is not routinely needed for uncomplicated cystitis but should be obtained for recurrent UTI, treatment failure, or atypical symptoms. ### First-Line Treatment | Agent | Dose | Duration | Key Considerations | |-------|------|----------|-------------------| | Nitrofurantoin | 100 mg BID | 5 days | Avoid if CrCl <30 or suspected pyelonephritis; minimal resistance impact | | TMP-SMX | 160/800 mg BID | 3 days | Avoid if local resistance >20%; check sulfa allergy | | Fosfomycin | 3 g single dose | 1 day | Lower efficacy; useful for ESBL organisms | Nitrofurantoin monohydrate/macrocrystals at 100 mg twice daily for 5 days is an excellent first-line choice because it concentrates in the urine with minimal resistance impact on gut flora. It should be avoided if creatinine clearance is below 30 mL/min (inadequate urinary concentration) or if pyelonephritis is suspected (it does not achieve systemic levels). Trimethoprim-sulfamethoxazole (TMP-SMX) at 160/800 mg twice daily for 3 days is another first-line option but should be avoided if local resistance exceeds 20% or with recent TMP-SMX use. Fosfomycin as a single 3 g dose offers convenience but has lower efficacy than nitrofurantoin or TMP-SMX; it is particularly useful for ESBL-producing organisms. ### Agents to Avoid for Uncomplicated Cystitis Fluoroquinolones (ciprofloxacin, levofloxacin) carry an FDA boxed warning for serious side effects including tendinopathy, peripheral neuropathy, CNS effects, and aortic dissection, and should be reserved for complicated UTI or pyelonephritis only. Amoxicillin and ampicillin have high resistance rates to E. coli. Cephalosporins are acceptable alternatives but promote more resistance than first-line agents. ## Complicated UTI ### Definition Complicated UTI occurs in patients with factors that increase the risk of treatment failure. These factors include male sex, pregnancy, immunosuppression, urinary tract abnormalities (obstruction, stones, stents, diversions), renal transplant, neurogenic bladder, and hospital-acquired or healthcare-associated infections. ### Management A urine culture should always be obtained before starting antibiotics. Empiric therapy depends on severity. For mild-to-moderate disease amenable to oral therapy, a fluoroquinolone (ciprofloxacin 500 mg twice daily for 7-14 days) or TMP-SMX (if susceptible) is appropriate. For moderate-to-severe disease requiring IV therapy, ceftriaxone 1 g IV daily, piperacillin-tazobactam, or meropenem (if ESBL risk factors are present) is used. Therapy should be narrowed based on culture results. Duration ranges from 7 to 14 days depending on clinical response and the agent used. The underlying complicating factor must be addressed, whether that means removing a stent or relieving an obstruction. ## Acute Pyelonephritis ### Clinical Features Pyelonephritis presents with fever, flank pain, costovertebral angle tenderness, and nausea or vomiting. Lower urinary tract symptoms may or may not be present. Laboratory findings include pyuria, bacteriuria, leukocytosis, and possible bacteremia. ### Diagnosis Urinalysis and urine culture should always be obtained. Blood cultures are indicated if the patient is systemically ill or hospitalized. CT of the abdomen and pelvis is pursued if there is no improvement within 48 to 72 hours, if obstruction or abscess is suspected, or if the presentation is atypical. ### Outpatient Treatment (Mild, Non-Toxic) Ciprofloxacin 500 mg twice daily for 7 days is appropriate, as fluoroquinolones are a reasonable choice for pyelonephritis unlike uncomplicated cystitis. Alternatively, TMP-SMX DS twice daily for 14 days can be used if the organism is susceptible. Ceftriaxone 1 g IM as a single dose while culture results are pending, followed by step-down to an oral agent, is another option. ### Inpatient Treatment (Severe, Septic) Ceftriaxone 1 g IV daily is the most common choice. IV fluoroquinolone is an alternative if the patient cannot take oral medications. Piperacillin-tazobactam or meropenem is used for complicated cases or when ESBL risk factors are present. Step-down to oral therapy occurs when the patient is clinically improving and culture sensitivities are available. Treatment algorithm for urinary tract infections showing uncomplicated cystitis (nitrofurantoin, TMP-SMX), complicated UTI, and pyelonephritis pathways with antibiotic choices and durations ## Catheter-Associated UTI (CAUTI) ### Definition (IDSA 2010) CAUTI is defined by symptoms or signs compatible with UTI (fever, suprapubic pain, costovertebral angle tenderness, new delirium, rigors) plus a positive urine culture (at or above 10^3 CFU/mL) in a patient with a current or recently removed indwelling catheter (within 48 hours). Catheter-associated asymptomatic bacteriuria should not be treated, as there is no benefit and treatment promotes resistance. ### Prevention Avoiding unnecessary catheterization is the single most important intervention. Catheters should be removed as soon as possible with daily reassessment of ongoing need. Proper insertion technique and maintenance of a closed drainage system with the bag kept below the bladder are essential. Nurse-driven catheter removal protocols have been shown to reduce CAUTI rates. When possible, condom catheters or intermittent catheterization are preferred over indwelling catheters. Antimicrobial-coated catheters offer modest benefit but are not universally recommended. ### Treatment The catheter should be removed or replaced before starting antibiotics because biofilm on the catheter harbors organisms and contributes to antibiotic failure. Culture should be obtained from the newly placed catheter, and antibiotic selection is guided by results. Duration is typically 7 days, with 10 to 14 days for patients with delayed clinical response. Candiduria usually represents colonization and should only be treated if symptomatic or in high-risk patients (neutropenic, renal transplant, planned urologic procedure), with fluconazole 200 mg daily as the treatment of choice. ## Recurrent UTIs in Women ### Definition Recurrent UTI is defined as 2 or more infections in 6 months or 3 or more in 12 months. ### Non-Antibiotic Prevention Strategies Behavioral measures include post-coital voiding (weak evidence but low risk) and adequate hydration. Vaginal estrogen in postmenopausal women restores vaginal lactobacilli and is effective for prevention. Cranberry products have modest evidence for prevention, with proanthocyanidins (PACs) possibly inhibiting bacterial adhesion. D-mannose has some evidence supporting its role in preventing E. coli adhesion to the urothelium. Methenamine hippurate is a urinary antiseptic with promising data as a non-antibiotic prophylactic agent. ### Antibiotic Prophylaxis Continuous low-dose prophylaxis options include nitrofurantoin 50-100 mg nightly or TMP-SMX half-tablet nightly. Post-coital prophylaxis with a single dose of nitrofurantoin or TMP-SMX after intercourse is effective for women with coitus-related UTIs. Patient-initiated therapy, in which well-educated and reliable patients self-start a 3-day treatment course at symptom onset, is another strategy. Prophylaxis is typically continued for 6 to 12 months before reassessment. Recurrent UTI prevention strategies showing non-antibiotic approaches (vaginal estrogen, cranberry, D-mannose, methenamine) and antibiotic prophylaxis options for women with recurrent cystitis ## UTIs in Men UTIs in men are almost always complicated, and an underlying cause should be investigated. The most common cause is benign prostatic hyperplasia, followed by urethral stricture, prostatitis, and kidney stones. Urine culture should always be obtained. Treatment consists of a fluoroquinolone or TMP-SMX for 7 to 14 days, with longer courses of 4 to 6 weeks when prostatitis is suspected. Chronic bacterial prostatitis should be considered in men with recurrent infections. Urologic referral is appropriate for recurrent UTIs or identified structural abnormalities. ## Clinical Pearls Urine culture in the absence of symptoms is a leading driver of inappropriate antibiotic use, and clinicians should not culture urine without a clinical indication. Foul-smelling urine, cloudy urine, and a positive urinalysis alone are not indications for antibiotics — the decision to treat is driven by symptoms. Nitrofurantoin is the ideal first-line agent for uncomplicated cystitis because it has maintained low resistance rates for decades through its multiple mechanisms of action and concentration in urine without disrupting gut flora. Fluoroquinolones should never be first-line for uncomplicated cystitis and must be reserved for pyelonephritis and complicated UTI. In elderly patients, delirium alone without other UTI symptoms is not sufficient to diagnose UTI, making this one of the most common diagnostic errors in hospital medicine. When treating CAUTI, always remove or replace the urinary catheter before initiating antibiotics, as antibiotic failure is common without biofilm disruption. ## References - Gupta K, et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women (IDSA/ESCMID). *Clin Infect Dis*. 2011;52:e103-e120. - Nicolle LE, et al. Clinical Practice Guideline for ASB in Adults (IDSA). *Clin Infect Dis*. 2019;68:e83-e110. - Hooton TM, et al. Diagnosis, Prevention, and Treatment of CAUTI (IDSA). *Clin Infect Dis*. 2010;50:625-663. - Anger J, et al. Recurrent Uncomplicated UTIs in Women (AUA/CUA/SUFU). *J Urol*. 2019;202:282-289. - FDA Drug Safety Communication: Fluoroquinolone Antibacterial Drugs. 2018.